Ocumension Therapeutics (HKG:1477)

Hong Kong · Delayed Price · Currency is HKD

5.09

+0.05 (0.89%)

Sep 30, 2026, 4:08 PM HKT

Market Cap	4.15B -38.9%
Revenue (ttm)	1.08B +71.8%
Net Income	-144.90M
EPS	-0.18
Shares Out	815.38M
PE Ratio	n/a
Forward PE	26.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,308,717
Open	5.26
Previous Close	5.04
Day's Range	5.01 - 5.26
52-Week Range	4.04 - 9.01
Beta	0.43
Analysts	Buy
Price Target	9.17 (+80.33%)
Est. Earnings	Nov 27, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation,... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 608

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1477

Full Company Profile

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 1477 stock is "Buy." The 12-month stock price target is $9.17, which is an increase of 80.33% from the latest price.

Price Target

$9.17

(80.33% upside)

Analyst Consensus: Buy

Stock Forecasts